AIMS: This study aimed to assess plasma fibroblast growth factor 23 (FGF23) in patients with heart failure with preserved ejection fraction (HFpEF) and its relation to inflammation, renal function, clinical and imaging characteristics, exercise capacity, and prognosis. METHODS AND RESULTS: We performed a prospective, observational study of 172 age-matched and sex-matched subjects (HFpEF n = 130; controls n = 42, age 73 ± 9, female 50%) who underwent plasma biomarker sampling, echocardiography, cardiac magnetic resonance imaging, and 6 min walk testing (6MWT). The primary endpoint was the composite of all-cause death or HF hospitalization. FGF23 was higher in HFpEF compared with controls (62 [42-105] vs. 34 [22-41] pg/mL, P < 0.0001). In HFpEF, FGF23 correlated with greater symptom burden (New York Heart Association class: r = 0.308), poorer exercise capacity (6MWT distance: r = -0.345), and plasma biomarkers reflecting inflammation (highly sensitive C-reactive protein: r = 0.207, myeloperoxidase: r = 0.311), bone metabolism (osteoprotegerin: r = 0.446), renal dysfunction (urea: r = 0.267, creatinine: r = 0.351, estimated glomerular filtration rate: r = -0.367), and echocardiographic E/e' (r = 0.298); P < 0.05. Following multivariable linear regression modelling, FGF23 remained independently associated with shorter 6MWT distance (P = 0.012) in addition to age, body mass index, and lower haemoglobin. During follow-up (median 1428 days), there were 61 composite events (21 deaths, 40 HF hospitalizations) in patients with HFpEF. In multivariable Cox regression analysis, FGF23 [adjusted hazard ratio (HR) 1.665; 95% confidence interval (CI) (1.284-2.160; P < 0.0001)], B-type natriuretic peptide (HR 1.433; CI 1.053-1.951; P = 0.022), and prior HF hospitalization (HR 2.058; CI 1.074-3.942; P = 0.030) were independent predictors of the composite endpoint. CONCLUSIONS: Plasma FGF23 is higher in HFpEF compared with age-matched and sex-matched controls and is strongly associated with exercise incapacity and prognosis. FGF23 correlates with plasma markers of inflammation and renal impairment.
AIMS: This study aimed to assess plasma fibroblast growth factor 23 (FGF23) in patients with heart failure with preserved ejection fraction (HFpEF) and its relation to inflammation, renal function, clinical and imaging characteristics, exercise capacity, and prognosis. METHODS AND RESULTS: We performed a prospective, observational study of 172 age-matched and sex-matched subjects (HFpEF n = 130; controls n = 42, age 73 ± 9, female 50%) who underwent plasma biomarker sampling, echocardiography, cardiac magnetic resonance imaging, and 6 min walk testing (6MWT). The primary endpoint was the composite of all-cause death or HF hospitalization. FGF23 was higher in HFpEF compared with controls (62 [42-105] vs. 34 [22-41] pg/mL, P < 0.0001). In HFpEF, FGF23 correlated with greater symptom burden (New York Heart Association class: r = 0.308), poorer exercise capacity (6MWT distance: r = -0.345), and plasma biomarkers reflecting inflammation (highly sensitive C-reactive protein: r = 0.207, myeloperoxidase: r = 0.311), bone metabolism (osteoprotegerin: r = 0.446), renal dysfunction (urea: r = 0.267, creatinine: r = 0.351, estimated glomerular filtration rate: r = -0.367), and echocardiographic E/e' (r = 0.298); P < 0.05. Following multivariable linear regression modelling, FGF23 remained independently associated with shorter 6MWT distance (P = 0.012) in addition to age, body mass index, and lower haemoglobin. During follow-up (median 1428 days), there were 61 composite events (21 deaths, 40 HF hospitalizations) in patients with HFpEF. In multivariable Cox regression analysis, FGF23 [adjusted hazard ratio (HR) 1.665; 95% confidence interval (CI) (1.284-2.160; P < 0.0001)], B-type natriuretic peptide (HR 1.433; CI 1.053-1.951; P = 0.022), and prior HF hospitalization (HR 2.058; CI 1.074-3.942; P = 0.030) were independent predictors of the composite endpoint. CONCLUSIONS: Plasma FGF23 is higher in HFpEF compared with age-matched and sex-matched controls and is strongly associated with exercise incapacity and prognosis. FGF23 correlates with plasma markers of inflammation and renal impairment.
Authors: Alexander Grabner; Ansel P Amaral; Karla Schramm; Saurav Singh; Alexis Sloan; Christopher Yanucil; Jihe Li; Lina A Shehadeh; Joshua M Hare; Valentin David; Aline Martin; Alessia Fornoni; Giovana Seno Di Marco; Dominik Kentrup; Stefan Reuter; Anna B Mayer; Hermann Pavenstädt; Jörg Stypmann; Christian Kuhn; Susanne Hille; Norbert Frey; Maren Leifheit-Nestler; Beatrice Richter; Dieter Haffner; Reimar Abraham; Johannes Bange; Bianca Sperl; Axel Ullrich; Marcus Brand; Myles Wolf; Christian Faul Journal: Cell Metab Date: 2015-10-01 Impact factor: 27.287
Authors: Rupal Mehta; Xuan Cai; Alexander Hodakowski; Jungwha Lee; Mary Leonard; Ana Ricardo; Jing Chen; Lee Hamm; James Sondheimer; Mirela Dobre; Valentin David; Wei Yang; Alan Go; John W Kusek; Harold Feldman; Myles Wolf; Tamara Isakova Journal: Clin J Am Soc Nephrol Date: 2017-08-07 Impact factor: 8.237
Authors: Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Alexander Grabner; Ansel Philip Amaral; Manfred Fobker; Jörg Stypmann; Hermann Pavenstädt; Myles Wolf; Christian Faul; Marcus Brand Journal: Nephrol Dial Transplant Date: 2014-05-29 Impact factor: 5.992
Authors: Burkert Pieske; Carsten Tschöpe; Rudolf A de Boer; Alan G Fraser; Stefan D Anker; Erwan Donal; Frank Edelmann; Michael Fu; Marco Guazzi; Carolyn S P Lam; Patrizio Lancellotti; Vojtech Melenovsky; Daniel A Morris; Eike Nagel; Elisabeth Pieske-Kraigher; Piotr Ponikowski; Scott D Solomon; Ramachandran S Vasan; Frans H Rutten; Adriaan A Voors; Frank Ruschitzka; Walter J Paulus; Petar Seferovic; Gerasimos Filippatos Journal: Eur Heart J Date: 2019-10-21 Impact factor: 29.983
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Prathap Kanagala; Jayanth R Arnold; Adrian S H Cheng; Anvesha Singh; Jamal N Khan; Gaurav S Gulsin; Jing Yang; Lei Zhao; Pankaj Gupta; Iain B Squire; Leong L Ng; Gerry P McCann Journal: Int J Cardiovasc Imaging Date: 2019-08-10 Impact factor: 2.357
Authors: Anne Cornelissen; Roberta Florescu; Kinan Kneizeh; Christian Cornelissen; Elisa Liehn; Vincent Brandenburg; Alexander Schuh Journal: J Clin Med Date: 2022-01-25 Impact factor: 4.241
Authors: Prathap Kanagala; Jayanth R Arnold; Jamal N Khan; Anvesha Singh; Gaurav S Gulsin; Iain B Squire; Gerry P McCann; Leong L Ng Journal: ESC Heart Fail Date: 2021-03-10
Authors: Prathap Kanagala; Jayanth R Arnold; Jamal N Khan; Anvesha Singh; Gaurav S Gulsin; Mohamed Eltayeb; Pankaj Gupta; Iain B Squire; Gerry P McCann; Leong L Ng Journal: ESC Heart Fail Date: 2020-09-16